About the Product

Description


Buspinil 5 Tablet contains Buspirone 5mg, a non-benzodiazepine anxiolytic used to manage generalized anxiety disorder (GAD) and tension-related symptoms. It modulates serotonin receptors to reduce excessive worry, nervousness, and irritability.

Belonging to the psychiatry and neurology segment, Buspinil 5 Tablet is commonly prescribed for mild to moderate anxiety cases and stress-related disorders. Its lower dose formulation is ideal for initial therapy, dose titration, or sensitive patients.

Buspirone is preferred due to its non-sedative and non-habit-forming profile, allowing patients to maintain daily activities without drowsiness or dependency risk.

For PCD pharma franchise partners, distributors, exporters, and third-party manufacturers, Buspinil 5 Tablet presents a high-demand B2B opportunity. Its essential use in psychiatric care ensures consistent prescriptions and a strong market presence across India.

Common side effects may include dizziness, headache, nausea, nervousness, or mild gastrointestinal discomfort. Rarely, allergic reactions, severe drowsiness, or confusion may occur. Seek medical attention if unusual symptoms appear.

Buspinil 5 Tablet is indicated for the treatment of generalized anxiety disorder (GAD) and short-term anxiety symptoms. It helps reduce tension, irritability, and nervousness, supporting better daily functioning.

Take Buspinil 5 Tablet exactly as prescribed. Avoid sudden discontinuation and inform your doctor if you have liver or kidney disorders, or are taking other central nervous system medications.

Store Buspinil 5 Tablet in a cool, dry place below 25°C, protected from sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Buspirone 5mg Tablet in the PCD pharma franchise market?

Buspirone 5mg Tablet has steady demand in the psychiatry (CNS) segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on anxiety and mental health therapy portfolios.

Why should medical distributors include Buspirone 5mg Tablet in their product range?

Medical distributors and agencies can benefit from consistent demand for management of generalized anxiety disorder (GAD), mild to moderate anxiety, and stress-related conditions. Buspirone is an anxiolytic that works on serotonin receptors and provides non-sedative anxiety relief This supports a reliable psychiatric prescription portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Buspirone 5mg Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong psychiatrist prescriptions, chronic anxiety treatment demand, steady long-term usage, growing mental health awareness, reliable supply chain support, and good margins in CNS medicines.

How can I become a distributor or franchise partner for Buspirone 5mg Tablet?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, territory rights, and distribution opportunities.